Global Viral Vector-Based Gene Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Viral Vector-Based Gene Therapy market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Viral Vector-Based Gene Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Viral Vector-Based Gene Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Gene Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Gene Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Gene Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vector-Based Gene Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vector-Based Gene Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sibiono, Rigvir Group, Shanghai Pharma (Sunway), Amgen, Spark Therapeutics, Novartis Gene Therapies, Daiichi Sankyo, PTC Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Viral Vector-Based Gene Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Adenovirus (AdV)
- Adeno-associated Virus (AAV)
Market segment by Application
- Hospital
- Clinic
- Others
Market segment by players, this report covers
- Sibiono
- Rigvir Group
- Shanghai Pharma (Sunway)
- Amgen
- Spark Therapeutics
- Novartis Gene Therapies
- Daiichi Sankyo
- PTC Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vector-Based Gene Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vector-Based Gene Therapy, with revenue, gross margin, and global market share of Viral Vector-Based Gene Therapy from 2020 to 2025.
Chapter 3, the Viral Vector-Based Gene Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Viral Vector-Based Gene Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector-Based Gene Therapy.
Chapter 13, to describe Viral Vector-Based Gene Therapy research findings and conclusion.
This report is a detailed and comprehensive analysis for global Viral Vector-Based Gene Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Viral Vector-Based Gene Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Gene Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Gene Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Viral Vector-Based Gene Therapy market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vector-Based Gene Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vector-Based Gene Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sibiono, Rigvir Group, Shanghai Pharma (Sunway), Amgen, Spark Therapeutics, Novartis Gene Therapies, Daiichi Sankyo, PTC Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Viral Vector-Based Gene Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Adenovirus (AdV)
- Adeno-associated Virus (AAV)
Market segment by Application
- Hospital
- Clinic
- Others
Market segment by players, this report covers
- Sibiono
- Rigvir Group
- Shanghai Pharma (Sunway)
- Amgen
- Spark Therapeutics
- Novartis Gene Therapies
- Daiichi Sankyo
- PTC Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vector-Based Gene Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vector-Based Gene Therapy, with revenue, gross margin, and global market share of Viral Vector-Based Gene Therapy from 2020 to 2025.
Chapter 3, the Viral Vector-Based Gene Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Viral Vector-Based Gene Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector-Based Gene Therapy.
Chapter 13, to describe Viral Vector-Based Gene Therapy research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Viral Vector-Based Gene Therapy by Type
1.3.1 Overview: Global Viral Vector-Based Gene Therapy Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Type in 2024
1.3.3 Adenovirus (AdV)
1.3.4 Adeno-associated Virus (AAV)
1.4 Global Viral Vector-Based Gene Therapy Market by Application
1.4.1 Overview: Global Viral Vector-Based Gene Therapy Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Viral Vector-Based Gene Therapy Market Size & Forecast
1.6 Global Viral Vector-Based Gene Therapy Market Size and Forecast by Region
1.6.1 Global Viral Vector-Based Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Viral Vector-Based Gene Therapy Market Size by Region, (2020-2031)
1.6.3 North America Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.4 Europe Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.6 South America Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Sibiono
2.1.1 Sibiono Details
2.1.2 Sibiono Major Business
2.1.3 Sibiono Viral Vector-Based Gene Therapy Product and Solutions
2.1.4 Sibiono Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Sibiono Recent Developments and Future Plans
2.2 Rigvir Group
2.2.1 Rigvir Group Details
2.2.2 Rigvir Group Major Business
2.2.3 Rigvir Group Viral Vector-Based Gene Therapy Product and Solutions
2.2.4 Rigvir Group Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Rigvir Group Recent Developments and Future Plans
2.3 Shanghai Pharma (Sunway)
2.3.1 Shanghai Pharma (Sunway) Details
2.3.2 Shanghai Pharma (Sunway) Major Business
2.3.3 Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Product and Solutions
2.3.4 Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Shanghai Pharma (Sunway) Recent Developments and Future Plans
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Viral Vector-Based Gene Therapy Product and Solutions
2.4.4 Amgen Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Amgen Recent Developments and Future Plans
2.5 Spark Therapeutics
2.5.1 Spark Therapeutics Details
2.5.2 Spark Therapeutics Major Business
2.5.3 Spark Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
2.5.4 Spark Therapeutics Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Spark Therapeutics Recent Developments and Future Plans
2.6 Novartis Gene Therapies
2.6.1 Novartis Gene Therapies Details
2.6.2 Novartis Gene Therapies Major Business
2.6.3 Novartis Gene Therapies Viral Vector-Based Gene Therapy Product and Solutions
2.6.4 Novartis Gene Therapies Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Novartis Gene Therapies Recent Developments and Future Plans
2.7 Daiichi Sankyo
2.7.1 Daiichi Sankyo Details
2.7.2 Daiichi Sankyo Major Business
2.7.3 Daiichi Sankyo Viral Vector-Based Gene Therapy Product and Solutions
2.7.4 Daiichi Sankyo Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Daiichi Sankyo Recent Developments and Future Plans
2.8 PTC Therapeutics
2.8.1 PTC Therapeutics Details
2.8.2 PTC Therapeutics Major Business
2.8.3 PTC Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
2.8.4 PTC Therapeutics Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 PTC Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Viral Vector-Based Gene Therapy Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Viral Vector-Based Gene Therapy by Company Revenue
3.2.2 Top 3 Viral Vector-Based Gene Therapy Players Market Share in 2024
3.2.3 Top 6 Viral Vector-Based Gene Therapy Players Market Share in 2024
3.3 Viral Vector-Based Gene Therapy Market: Overall Company Footprint Analysis
3.3.1 Viral Vector-Based Gene Therapy Market: Region Footprint
3.3.2 Viral Vector-Based Gene Therapy Market: Company Product Type Footprint
3.3.3 Viral Vector-Based Gene Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Viral Vector-Based Gene Therapy Consumption Value and Market Share by Type (2020-2025)
4.2 Global Viral Vector-Based Gene Therapy Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2025)
5.2 Global Viral Vector-Based Gene Therapy Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
6.2 North America Viral Vector-Based Gene Therapy Market Size by Application (2020-2031)
6.3 North America Viral Vector-Based Gene Therapy Market Size by Country
6.3.1 North America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
6.3.2 United States Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
6.3.3 Canada Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
6.3.4 Mexico Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
7.2 Europe Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
7.3 Europe Viral Vector-Based Gene Therapy Market Size by Country
7.3.1 Europe Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
7.3.2 Germany Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.3 France Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.5 Russia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.6 Italy Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Viral Vector-Based Gene Therapy Market Size by Region
8.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Region (2020-2031)
8.3.2 China Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.3 Japan Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.4 South Korea Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.5 India Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.7 Australia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
9.2 South America Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
9.3 South America Viral Vector-Based Gene Therapy Market Size by Country
9.3.1 South America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
9.3.2 Brazil Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
9.3.3 Argentina Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Viral Vector-Based Gene Therapy Market Size by Country
10.3.1 Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
10.3.2 Turkey Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
10.3.4 UAE Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Viral Vector-Based Gene Therapy Market Drivers
11.2 Viral Vector-Based Gene Therapy Market Restraints
11.3 Viral Vector-Based Gene Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Viral Vector-Based Gene Therapy Industry Chain
12.2 Viral Vector-Based Gene Therapy Upstream Analysis
12.3 Viral Vector-Based Gene Therapy Midstream Analysis
12.4 Viral Vector-Based Gene Therapy Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Viral Vector-Based Gene Therapy by Type
1.3.1 Overview: Global Viral Vector-Based Gene Therapy Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Type in 2024
1.3.3 Adenovirus (AdV)
1.3.4 Adeno-associated Virus (AAV)
1.4 Global Viral Vector-Based Gene Therapy Market by Application
1.4.1 Overview: Global Viral Vector-Based Gene Therapy Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Viral Vector-Based Gene Therapy Market Size & Forecast
1.6 Global Viral Vector-Based Gene Therapy Market Size and Forecast by Region
1.6.1 Global Viral Vector-Based Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Viral Vector-Based Gene Therapy Market Size by Region, (2020-2031)
1.6.3 North America Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.4 Europe Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.6 South America Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Viral Vector-Based Gene Therapy Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Sibiono
2.1.1 Sibiono Details
2.1.2 Sibiono Major Business
2.1.3 Sibiono Viral Vector-Based Gene Therapy Product and Solutions
2.1.4 Sibiono Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Sibiono Recent Developments and Future Plans
2.2 Rigvir Group
2.2.1 Rigvir Group Details
2.2.2 Rigvir Group Major Business
2.2.3 Rigvir Group Viral Vector-Based Gene Therapy Product and Solutions
2.2.4 Rigvir Group Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Rigvir Group Recent Developments and Future Plans
2.3 Shanghai Pharma (Sunway)
2.3.1 Shanghai Pharma (Sunway) Details
2.3.2 Shanghai Pharma (Sunway) Major Business
2.3.3 Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Product and Solutions
2.3.4 Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Shanghai Pharma (Sunway) Recent Developments and Future Plans
2.4 Amgen
2.4.1 Amgen Details
2.4.2 Amgen Major Business
2.4.3 Amgen Viral Vector-Based Gene Therapy Product and Solutions
2.4.4 Amgen Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Amgen Recent Developments and Future Plans
2.5 Spark Therapeutics
2.5.1 Spark Therapeutics Details
2.5.2 Spark Therapeutics Major Business
2.5.3 Spark Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
2.5.4 Spark Therapeutics Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Spark Therapeutics Recent Developments and Future Plans
2.6 Novartis Gene Therapies
2.6.1 Novartis Gene Therapies Details
2.6.2 Novartis Gene Therapies Major Business
2.6.3 Novartis Gene Therapies Viral Vector-Based Gene Therapy Product and Solutions
2.6.4 Novartis Gene Therapies Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Novartis Gene Therapies Recent Developments and Future Plans
2.7 Daiichi Sankyo
2.7.1 Daiichi Sankyo Details
2.7.2 Daiichi Sankyo Major Business
2.7.3 Daiichi Sankyo Viral Vector-Based Gene Therapy Product and Solutions
2.7.4 Daiichi Sankyo Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Daiichi Sankyo Recent Developments and Future Plans
2.8 PTC Therapeutics
2.8.1 PTC Therapeutics Details
2.8.2 PTC Therapeutics Major Business
2.8.3 PTC Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
2.8.4 PTC Therapeutics Viral Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 PTC Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Viral Vector-Based Gene Therapy Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Viral Vector-Based Gene Therapy by Company Revenue
3.2.2 Top 3 Viral Vector-Based Gene Therapy Players Market Share in 2024
3.2.3 Top 6 Viral Vector-Based Gene Therapy Players Market Share in 2024
3.3 Viral Vector-Based Gene Therapy Market: Overall Company Footprint Analysis
3.3.1 Viral Vector-Based Gene Therapy Market: Region Footprint
3.3.2 Viral Vector-Based Gene Therapy Market: Company Product Type Footprint
3.3.3 Viral Vector-Based Gene Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Viral Vector-Based Gene Therapy Consumption Value and Market Share by Type (2020-2025)
4.2 Global Viral Vector-Based Gene Therapy Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2025)
5.2 Global Viral Vector-Based Gene Therapy Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
6.2 North America Viral Vector-Based Gene Therapy Market Size by Application (2020-2031)
6.3 North America Viral Vector-Based Gene Therapy Market Size by Country
6.3.1 North America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
6.3.2 United States Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
6.3.3 Canada Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
6.3.4 Mexico Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
7.2 Europe Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
7.3 Europe Viral Vector-Based Gene Therapy Market Size by Country
7.3.1 Europe Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
7.3.2 Germany Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.3 France Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.5 Russia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
7.3.6 Italy Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Viral Vector-Based Gene Therapy Market Size by Region
8.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Region (2020-2031)
8.3.2 China Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.3 Japan Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.4 South Korea Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.5 India Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
8.3.7 Australia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
9.2 South America Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
9.3 South America Viral Vector-Based Gene Therapy Market Size by Country
9.3.1 South America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
9.3.2 Brazil Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
9.3.3 Argentina Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Viral Vector-Based Gene Therapy Market Size by Country
10.3.1 Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2031)
10.3.2 Turkey Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
10.3.4 UAE Viral Vector-Based Gene Therapy Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Viral Vector-Based Gene Therapy Market Drivers
11.2 Viral Vector-Based Gene Therapy Market Restraints
11.3 Viral Vector-Based Gene Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Viral Vector-Based Gene Therapy Industry Chain
12.2 Viral Vector-Based Gene Therapy Upstream Analysis
12.3 Viral Vector-Based Gene Therapy Midstream Analysis
12.4 Viral Vector-Based Gene Therapy Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Viral Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Viral Vector-Based Gene Therapy Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Viral Vector-Based Gene Therapy Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Viral Vector-Based Gene Therapy Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Sibiono Company Information, Head Office, and Major Competitors
Table 6. Sibiono Major Business
Table 7. Sibiono Viral Vector-Based Gene Therapy Product and Solutions
Table 8. Sibiono Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Sibiono Recent Developments and Future Plans
Table 10. Rigvir Group Company Information, Head Office, and Major Competitors
Table 11. Rigvir Group Major Business
Table 12. Rigvir Group Viral Vector-Based Gene Therapy Product and Solutions
Table 13. Rigvir Group Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Rigvir Group Recent Developments and Future Plans
Table 15. Shanghai Pharma (Sunway) Company Information, Head Office, and Major Competitors
Table 16. Shanghai Pharma (Sunway) Major Business
Table 17. Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Product and Solutions
Table 18. Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Amgen Company Information, Head Office, and Major Competitors
Table 20. Amgen Major Business
Table 21. Amgen Viral Vector-Based Gene Therapy Product and Solutions
Table 22. Amgen Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Amgen Recent Developments and Future Plans
Table 24. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 25. Spark Therapeutics Major Business
Table 26. Spark Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
Table 27. Spark Therapeutics Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Spark Therapeutics Recent Developments and Future Plans
Table 29. Novartis Gene Therapies Company Information, Head Office, and Major Competitors
Table 30. Novartis Gene Therapies Major Business
Table 31. Novartis Gene Therapies Viral Vector-Based Gene Therapy Product and Solutions
Table 32. Novartis Gene Therapies Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Novartis Gene Therapies Recent Developments and Future Plans
Table 34. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 35. Daiichi Sankyo Major Business
Table 36. Daiichi Sankyo Viral Vector-Based Gene Therapy Product and Solutions
Table 37. Daiichi Sankyo Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Daiichi Sankyo Recent Developments and Future Plans
Table 39. PTC Therapeutics Company Information, Head Office, and Major Competitors
Table 40. PTC Therapeutics Major Business
Table 41. PTC Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
Table 42. PTC Therapeutics Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. PTC Therapeutics Recent Developments and Future Plans
Table 44. Global Viral Vector-Based Gene Therapy Revenue (USD Million) by Players (2020-2025)
Table 45. Global Viral Vector-Based Gene Therapy Revenue Share by Players (2020-2025)
Table 46. Breakdown of Viral Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 47. Market Position of Players in Viral Vector-Based Gene Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 48. Head Office of Key Viral Vector-Based Gene Therapy Players
Table 49. Viral Vector-Based Gene Therapy Market: Company Product Type Footprint
Table 50. Viral Vector-Based Gene Therapy Market: Company Product Application Footprint
Table 51. Viral Vector-Based Gene Therapy New Market Entrants and Barriers to Market Entry
Table 52. Viral Vector-Based Gene Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 53. Global Viral Vector-Based Gene Therapy Consumption Value (USD Million) by Type (2020-2025)
Table 54. Global Viral Vector-Based Gene Therapy Consumption Value Share by Type (2020-2025)
Table 55. Global Viral Vector-Based Gene Therapy Consumption Value Forecast by Type (2026-2031)
Table 56. Global Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025)
Table 57. Global Viral Vector-Based Gene Therapy Consumption Value Forecast by Application (2026-2031)
Table 58. North America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 59. North America Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 60. North America Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 61. North America Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 62. North America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 63. North America Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 64. Europe Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 65. Europe Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 66. Europe Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 67. Europe Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 68. Europe Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 69. Europe Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 70. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 71. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 72. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 73. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 74. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Region (2020-2025) & (USD Million)
Table 75. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Region (2026-2031) & (USD Million)
Table 76. South America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 77. South America Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 78. South America Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 79. South America Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 80. South America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 81. South America Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 82. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 83. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 84. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 85. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 86. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 87. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 88. Global Key Players of Viral Vector-Based Gene Therapy Upstream (Raw Materials)
Table 89. Global Viral Vector-Based Gene Therapy Typical Customers
Table 1. Global Viral Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Viral Vector-Based Gene Therapy Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Viral Vector-Based Gene Therapy Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Viral Vector-Based Gene Therapy Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Sibiono Company Information, Head Office, and Major Competitors
Table 6. Sibiono Major Business
Table 7. Sibiono Viral Vector-Based Gene Therapy Product and Solutions
Table 8. Sibiono Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Sibiono Recent Developments and Future Plans
Table 10. Rigvir Group Company Information, Head Office, and Major Competitors
Table 11. Rigvir Group Major Business
Table 12. Rigvir Group Viral Vector-Based Gene Therapy Product and Solutions
Table 13. Rigvir Group Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Rigvir Group Recent Developments and Future Plans
Table 15. Shanghai Pharma (Sunway) Company Information, Head Office, and Major Competitors
Table 16. Shanghai Pharma (Sunway) Major Business
Table 17. Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Product and Solutions
Table 18. Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Amgen Company Information, Head Office, and Major Competitors
Table 20. Amgen Major Business
Table 21. Amgen Viral Vector-Based Gene Therapy Product and Solutions
Table 22. Amgen Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Amgen Recent Developments and Future Plans
Table 24. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 25. Spark Therapeutics Major Business
Table 26. Spark Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
Table 27. Spark Therapeutics Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Spark Therapeutics Recent Developments and Future Plans
Table 29. Novartis Gene Therapies Company Information, Head Office, and Major Competitors
Table 30. Novartis Gene Therapies Major Business
Table 31. Novartis Gene Therapies Viral Vector-Based Gene Therapy Product and Solutions
Table 32. Novartis Gene Therapies Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Novartis Gene Therapies Recent Developments and Future Plans
Table 34. Daiichi Sankyo Company Information, Head Office, and Major Competitors
Table 35. Daiichi Sankyo Major Business
Table 36. Daiichi Sankyo Viral Vector-Based Gene Therapy Product and Solutions
Table 37. Daiichi Sankyo Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Daiichi Sankyo Recent Developments and Future Plans
Table 39. PTC Therapeutics Company Information, Head Office, and Major Competitors
Table 40. PTC Therapeutics Major Business
Table 41. PTC Therapeutics Viral Vector-Based Gene Therapy Product and Solutions
Table 42. PTC Therapeutics Viral Vector-Based Gene Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. PTC Therapeutics Recent Developments and Future Plans
Table 44. Global Viral Vector-Based Gene Therapy Revenue (USD Million) by Players (2020-2025)
Table 45. Global Viral Vector-Based Gene Therapy Revenue Share by Players (2020-2025)
Table 46. Breakdown of Viral Vector-Based Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 47. Market Position of Players in Viral Vector-Based Gene Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 48. Head Office of Key Viral Vector-Based Gene Therapy Players
Table 49. Viral Vector-Based Gene Therapy Market: Company Product Type Footprint
Table 50. Viral Vector-Based Gene Therapy Market: Company Product Application Footprint
Table 51. Viral Vector-Based Gene Therapy New Market Entrants and Barriers to Market Entry
Table 52. Viral Vector-Based Gene Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 53. Global Viral Vector-Based Gene Therapy Consumption Value (USD Million) by Type (2020-2025)
Table 54. Global Viral Vector-Based Gene Therapy Consumption Value Share by Type (2020-2025)
Table 55. Global Viral Vector-Based Gene Therapy Consumption Value Forecast by Type (2026-2031)
Table 56. Global Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025)
Table 57. Global Viral Vector-Based Gene Therapy Consumption Value Forecast by Application (2026-2031)
Table 58. North America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 59. North America Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 60. North America Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 61. North America Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 62. North America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 63. North America Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 64. Europe Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 65. Europe Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 66. Europe Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 67. Europe Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 68. Europe Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 69. Europe Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 70. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 71. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 72. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 73. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 74. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Region (2020-2025) & (USD Million)
Table 75. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value by Region (2026-2031) & (USD Million)
Table 76. South America Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 77. South America Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 78. South America Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 79. South America Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 80. South America Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 81. South America Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 82. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Type (2020-2025) & (USD Million)
Table 83. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Type (2026-2031) & (USD Million)
Table 84. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Application (2020-2025) & (USD Million)
Table 85. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Application (2026-2031) & (USD Million)
Table 86. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Country (2020-2025) & (USD Million)
Table 87. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value by Country (2026-2031) & (USD Million)
Table 88. Global Key Players of Viral Vector-Based Gene Therapy Upstream (Raw Materials)
Table 89. Global Viral Vector-Based Gene Therapy Typical Customers
LIST OF FIGURES
Figure 1. Viral Vector-Based Gene Therapy Picture
Figure 2. Global Viral Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Type in 2024
Figure 4. Adenovirus (AdV)
Figure 5. Adeno-associated Virus (AAV)
Figure 6. Global Viral Vector-Based Gene Therapy Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 7. Viral Vector-Based Gene Therapy Consumption Value Market Share by Application in 2024
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Others Picture
Figure 11. Global Viral Vector-Based Gene Therapy Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 12. Global Viral Vector-Based Gene Therapy Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 13. Global Market Viral Vector-Based Gene Therapy Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 14. Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Region (2020-2031)
Figure 15. Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Region in 2024
Figure 16. North America Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 17. Europe Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 18. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 19. South America Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 20. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 21. Company Three Recent Developments and Future Plans
Figure 22. Global Viral Vector-Based Gene Therapy Revenue Share by Players in 2024
Figure 23. Viral Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 24. Market Share of Viral Vector-Based Gene Therapy by Player Revenue in 2024
Figure 25. Top 3 Viral Vector-Based Gene Therapy Players Market Share in 2024
Figure 26. Top 6 Viral Vector-Based Gene Therapy Players Market Share in 2024
Figure 27. Global Viral Vector-Based Gene Therapy Consumption Value Share by Type (2020-2025)
Figure 28. Global Viral Vector-Based Gene Therapy Market Share Forecast by Type (2026-2031)
Figure 29. Global Viral Vector-Based Gene Therapy Consumption Value Share by Application (2020-2025)
Figure 30. Global Viral Vector-Based Gene Therapy Market Share Forecast by Application (2026-2031)
Figure 31. North America Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 32. North America Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 33. North America Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 34. United States Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 35. Canada Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 36. Mexico Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 37. Europe Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 38. Europe Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 39. Europe Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 40. Germany Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 41. France Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 42. United Kingdom Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 43. Russia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 44. Italy Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 45. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 46. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 47. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value Market Share by Region (2020-2031)
Figure 48. China Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 49. Japan Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 50. South Korea Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 51. India Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 52. Southeast Asia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 53. Australia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 54. South America Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 55. South America Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 56. South America Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 57. Brazil Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 58. Argentina Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 59. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 60. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 61. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 62. Turkey Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 63. Saudi Arabia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 64. UAE Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 65. Viral Vector-Based Gene Therapy Market Drivers
Figure 66. Viral Vector-Based Gene Therapy Market Restraints
Figure 67. Viral Vector-Based Gene Therapy Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Viral Vector-Based Gene Therapy Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Figure 1. Viral Vector-Based Gene Therapy Picture
Figure 2. Global Viral Vector-Based Gene Therapy Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Type in 2024
Figure 4. Adenovirus (AdV)
Figure 5. Adeno-associated Virus (AAV)
Figure 6. Global Viral Vector-Based Gene Therapy Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 7. Viral Vector-Based Gene Therapy Consumption Value Market Share by Application in 2024
Figure 8. Hospital Picture
Figure 9. Clinic Picture
Figure 10. Others Picture
Figure 11. Global Viral Vector-Based Gene Therapy Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 12. Global Viral Vector-Based Gene Therapy Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 13. Global Market Viral Vector-Based Gene Therapy Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 14. Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Region (2020-2031)
Figure 15. Global Viral Vector-Based Gene Therapy Consumption Value Market Share by Region in 2024
Figure 16. North America Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 17. Europe Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 18. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 19. South America Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 20. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 21. Company Three Recent Developments and Future Plans
Figure 22. Global Viral Vector-Based Gene Therapy Revenue Share by Players in 2024
Figure 23. Viral Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 24. Market Share of Viral Vector-Based Gene Therapy by Player Revenue in 2024
Figure 25. Top 3 Viral Vector-Based Gene Therapy Players Market Share in 2024
Figure 26. Top 6 Viral Vector-Based Gene Therapy Players Market Share in 2024
Figure 27. Global Viral Vector-Based Gene Therapy Consumption Value Share by Type (2020-2025)
Figure 28. Global Viral Vector-Based Gene Therapy Market Share Forecast by Type (2026-2031)
Figure 29. Global Viral Vector-Based Gene Therapy Consumption Value Share by Application (2020-2025)
Figure 30. Global Viral Vector-Based Gene Therapy Market Share Forecast by Application (2026-2031)
Figure 31. North America Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 32. North America Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 33. North America Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 34. United States Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 35. Canada Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 36. Mexico Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 37. Europe Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 38. Europe Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 39. Europe Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 40. Germany Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 41. France Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 42. United Kingdom Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 43. Russia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 44. Italy Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 45. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 46. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 47. Asia-Pacific Viral Vector-Based Gene Therapy Consumption Value Market Share by Region (2020-2031)
Figure 48. China Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 49. Japan Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 50. South Korea Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 51. India Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 52. Southeast Asia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 53. Australia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 54. South America Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 55. South America Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 56. South America Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 57. Brazil Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 58. Argentina Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 59. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value Market Share by Type (2020-2031)
Figure 60. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value Market Share by Application (2020-2031)
Figure 61. Middle East & Africa Viral Vector-Based Gene Therapy Consumption Value Market Share by Country (2020-2031)
Figure 62. Turkey Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 63. Saudi Arabia Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 64. UAE Viral Vector-Based Gene Therapy Consumption Value (2020-2031) & (USD Million)
Figure 65. Viral Vector-Based Gene Therapy Market Drivers
Figure 66. Viral Vector-Based Gene Therapy Market Restraints
Figure 67. Viral Vector-Based Gene Therapy Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Viral Vector-Based Gene Therapy Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
